Sign in
Enrolling by invitationPhase 3

Long-term study of ACP-204 for psychosis linked to Alzheimer's disease

Checks the long-term safety of ACP-204 in older adults with Alzheimer's psychosis.

Key facts

Who runs it
ACADIA Pharmaceuticals Inc.
Where
Incheon and Seoul, South KoreaSee the 5 sitesAlso in 11 other countries, 101 sites
Registry title
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Status
Enrolling by invitation
Phase
Phase 3
People taking part
752 people, planned
Started
23 Apr 2024
Expected to end
May 2029
Type of study
Interventional
Treatments tested
  • ACP-204
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Alzheimer's disease psychosis who finished the earlier ACP-204-006 study and have a caregiver to attend visits with them.

Age
55 to 95 years old
Sex
Men and women. Women must not be able to become pregnant. Men must use appropriate contraception if their partner could become pregnant.
Disease stage
Alzheimer's disease psychosis
Earlier treatment
Must have successfully completed the ACP-204-006 study.

Main reasons for not taking part

  • Needs a medication that the study does not allow
  • In hospice with end-of-life palliative care, or bedridden
  • Unstable, clinically significant medical condition other than Alzheimer's disease
  • Any medical condition that the investigator thinks may affect safety or the ability to finish the study

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Subject has successfully completed ACP-204-006 study
  • Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential
  • Subject has a designated study partner/caregiver
  • Subjects are able to complete all study visits with a study partner/caregiver
  • Signed inform consent form with a caregiver or legal representative

Who cannot take part

  • Requires treatment with a medication prohibited by the protocol
  • Is in hospice and receiving end-of-life palliative care, or has become bedridden
  • Unstable clinically significant medical condition other than AD
  • Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study; Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 55 and 95 years old?

Where in South Korea

Also in 11 other countries, 101 sites

  • Inha University HospitalIncheon, South KoreaEnrolling by invitation
  • Hanyang University Seoul HospitalSeoul, South KoreaEnrolling by invitation
  • Samsung Medical CenterSeoul, South KoreaEnrolling by invitation
  • Seoul National University Boramae Medical CenterSeoul, South KoreaEnrolling by invitation
  • The Catholic University of KoreaSeoul, South KoreaEnrolling by invitation

About the trial

What the trial wants to find out

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

The group in the trial

  • ACP-204Treatment being tested

    ACP-204 30mg or 60mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
Plain-language title
Long-term study of ACP-204 for psychosis linked to Alzheimer's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT06194799, who can take part
Record updated
4 November 2026